Did you know? Every 8 minutes, another person is added to the transplant waiting list. Be a hero to one of the more than 100,000 people on transplant waiting lists. Join the cause. Consider becoming an organ donor. https://www.organdonor.gov Source: Health Resources & Services Administration. #OrganDonation #TransplantMedicine
Veloxis Pharmaceuticals, Inc.
生物技术研究
Cary,North Carolina 10,100 位关注者
Let's transform transplant medicine. Together
关于我们
Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Read our Community Guidelines: https://bit.ly/3FQr7Wg
- 网站
-
https://www.veloxis.com
Veloxis Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cary,North Carolina
- 类型
- 上市公司
- 领域
- Pharmaceuticals、Biotechnology和Transplant
地点
-
主要
2000 Regency Pkwy
Suite 500
US,North Carolina,Cary,27518
Veloxis Pharmaceuticals, Inc.员工
动态
-
Thanks to everyone who participated in our poll this week! The answer is: Approximately 28,000 kidney transplants took place in the U.S. in 2023. Source: US Department of Health and Human Services. #OrganDonation #TransplantMedicine
-
Every year, thousands of lives are saved thanks to organ donations. Source: US Department of Health and Human Services. #OrganDonation #TransplantMedicine
此处无法显示此内容
在领英 APP 中访问此内容等
-
Navigating the transplant journey can be difficult, but we’re in this together. Veloxis is proud to support the medical societies and patient advocacy organizations working to build a thriving transplant community. Get started interacting with others in the community. https://lnkd.in/gvj_WGBk #OrganDonation #TransplantMedicine
-
At Veloxis, our focus is innovating and developing essential transplant medications. And, we do this by working with stakeholders at every level of transplant care. ? With so much at stake for transplant recipients and their families, let’s work together for the transplant community. By combining Veloxis’s infrastructure and capabilities with your experience and expertise, we can partner to develop transplant medications to improve patients’ lives. ? Are you ready to transform transplant medicine together? Join our mission. ? #OrganDonation #AKhealthcare #TransplantMedicine
-
Veloxis Pharmaceuticals is honored to be a sponsor of one of the largest gatherings of transplant recipients in the world: The 2024 Transplant Games of America in Birmingham, AL, on July 5-10! An initiative of the Transplant Life Foundation, the Transplant Games of America raises awareness of the transplant community and honors donors who have given the gift of life. Recipients of organs, eyes, and tissue join living donors, donor families, those on the waiting list, and transplant professionals to celebrate the tremendous impact donations have on the world. Learn more at the Transplant Games of America’s website. #TGA24BHM #Transplant #DonateLife #OrganDonation #TransplantGames
Transplant Games of America 2024
transplantgamesofamerica.org
-
Did you know that you can give the #GiftOfLife? Every organ donor can save up to 8 lives and enhance over 75 more! Every donation helps—register to become an organ, eye, and tissue donor. #OrganDonation
Register to be an Organ, Eye and Tissue Donor
registerme.org
-
We’re excited to be in the City of Brotherly Love for this year’s American Transplant Congress. Visit us at Booth 613! #ATC2024Philly
-
We’re excited about the new clinical data on VEL-101 (also known as FR104) that will be presented at #ATC2024Philly! Three research abstracts will be presented, including one by our very own Simon Tremblay, PharmD, PhD. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients. Read more here: https://bit.ly/vel-101